Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Operating Expenses (2016 - 2021)

Historic Operating Expenses for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to $251.5 million.

  • Neurocrine Biosciences' Operating Expenses fell 1694.19% to $251.5 million in Q3 2021 from the same period last year, while for Dec 2021 it was $682.7 million, marking a year-over-year decrease of 2267.53%. This contributed to the annual value of $882.9 million for FY2020, which is 2334.45% up from last year.
  • Per Neurocrine Biosciences' latest filing, its Operating Expenses stood at $251.5 million for Q3 2021, which was down 1694.19% from $226.1 million recorded in Q2 2021.
  • Neurocrine Biosciences' 5-year Operating Expenses high stood at $302.8 million for Q3 2020, and its period low was $63.6 million during Q2 2017.
  • In the last 5 years, Neurocrine Biosciences' Operating Expenses had a median value of $149.1 million in 2019 and averaged $157.3 million.
  • Within the past 5 years, the most significant YoY rise in Neurocrine Biosciences' Operating Expenses was 12939.39% (2020), while the steepest drop was 2556.39% (2020).
  • Over the past 5 years, Neurocrine Biosciences' Operating Expenses (Quarter) stood at $82.7 million in 2017, then soared by 32.58% to $109.6 million in 2018, then surged by 78.16% to $195.3 million in 2019, then dropped by 9.83% to $176.1 million in 2020, then skyrocketed by 42.82% to $251.5 million in 2021.
  • Its Operating Expenses stands at $251.5 million for Q3 2021, versus $226.1 million for Q2 2021 and $205.1 million for Q1 2021.